Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease

• Главные авторы: Marloes Dankers (Автор), Marjorie H. J. M. G. Nelissen-Vrancken (Автор), Sara M. K. Surminski (Автор), Anke C. Lambooij (Автор), Tjard R. Schermer (Автор), Liset van Dijk (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2020-02-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

BackgroundRegistration authorities evaluate effects of new medicines for chronic obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status and exacerbations. To establish clinical relevance, minimal clinically important differences (MCIDs) are used. The aim of this study was...